Rachel Penn

QbD is the most effective way to protect participants and data in clinical trials, yet the industry still struggles to make it a priority.

TRI’s GCP e-learning module turns ICH E6(R3) principles into practical, scenario-based training.

Risk-based approaches are everyone’s top priority in clinical trials, but no one seems to have a clear playbook.

TRI CEO Duncan Hall will be at Scope Europe 2025, sharing how technology is meeting the evolving needs of RBQM.

Despite high awareness, ICH E6(R3) adoption is stalling, only 19% of organizations report significant change.

Early alignment on risk tolerance is essential to ensure efficient, compliant trial execution.

TRI Fest 2025 brought our team together for a day of collaboration and a bit of friendly chaos.

This World Patient Safety Day, we’re shining a light on how healthcare professionals can build safety into every interaction.

This webinar unpacked the major shifts in ICH E6 (R3), showing how teams can embrace RBQM.

ICH E6 (R3) is here, but only 19% of the industry is ready. While awareness is high, meaningful action is lagging.